Gone but Not Forgotten: Retracted COVID-19 Papers Still Cited
University of Wollongong epidemiologist Gideon Meyerowitz-Katz speaks with The Scientist about his team’s finding that flawed and fraudulent COVID-19 research continues to be cited.
Gone but Not Forgotten: Retracted COVID-19 Papers Still Cited
Gone but Not Forgotten: Retracted COVID-19 Papers Still Cited
University of Wollongong epidemiologist Gideon Meyerowitz-Katz speaks with The Scientist about his team’s finding that flawed and fraudulent COVID-19 research continues to be cited.
University of Wollongong epidemiologist Gideon Meyerowitz-Katz speaks with The Scientist about his team’s finding that flawed and fraudulent COVID-19 research continues to be cited.
Governments are variable in their reliance on highly cited research, while international intergovernmental organizations such as the World Health Organization reliably link policy and science, according to an analysis of thousands of policy documents from the first half of 2020.
China shows the biggest increase of any country in the number of scientists listed since last year, while cancer genomics emerges as one of the more dominant fields.
Consortium pushes for open citation data; Gates Foundation launches open-access publishing platform; Cell Press lifts the veil on papers under consideration; an online widget circumvents some paywalls
According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.
Thomson Reuters has transferred the science-citation database, along with the rest of its intellectual property and science division, to private-equity firms.
Researchers find that scientific papers with shorter titles accrue more citations only if they are very popular. For papers flying under the radar, longer titles fare better.